Deadline Soon: Red Cat Holdings, Inc. (RCAT) Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
IF YOU ARE AN INVESTOR WHO LOST MONEY ON RED CAT HOLDINGS, INC. (RCAT), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT.
What Happened?
In March 2022, Red Cat announced that its subsidiary Teal Drones, Inc. ('Teal') had been selected to compete in Tranche 2 of the U.S. Army's Short Range Reconnaissance Program of Record (the 'SRR Program').
On July 27, 2023, Red Cat released its fiscal year 2023 financial results and revealed that its Salt Lake City Facility could only produce 100 drones per month and that construction of the facility was only 'substantially completed' and, while it could potentially reach a production capacity of one thousand drones per month over the next two to three years, it would require additional capital investments.
On this news, Red Cat's stock price fell $0.10, or 8.9%, to close at $1.02 per share on July 28, 2023, thereby injuring investors.
Then, on September 23, 2024, Red Cat released its first quarter fiscal 2025 financial results, missing consensus estimates and disclosing that it had spent 'the past four months . . . retooling [the Salt Lake City Facility] and preparing for high volume production[,]' while admitting that a 'pause in manufacturing of Teal 2 and building our Army prototypes impacted Teal 2 sales' because it 'couldn't produce and sell Teal 2 units while retooling [its] factory.'
On this news, Red Cat's stock price fell $0.80, or 25.3%, over two consecutive trading days to close at $2.36 per share on September 25, 2024.
Then, on November 19, 2024, Red Cat announced that it had won the SRR contract, stating that it was worth potentially hundreds of millions of dollars.
However, on January 16, 2025, Kerrisdale Capital published a report alleging, among other things, that Red Cat had overstated that value of the SRR Contract and that it was worth approximately $20-25 million, based on U.S. Army budget documents.
On this news, Red Cat's stock price fell $2.35, or 21.5%, over two consecutive trading days to close at $8.56 per share on January 17, 2025, thereby injuring investors further.
What Is the Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Salt Lake City Facility's production capacity, and Defendants' progress in developing the same, was overstated; (2) the overall value of the SRR Contract was overstated; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired Red Cat securities between March 18, 2022 and January 15, 2025, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is July 22, 2025.
Contact Us to Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us:
Frank R. Cruz
The Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Century City, California 90067
Email us at: info@frankcruzlaw.com
Call us at: 310-914-5007
Visit our website at www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
Palantir Stock Wins a New Street-High Price Target, But Is There Any Upside Left?
Palantir (NASDAQ:PLTR) stock has its roots in a company unafraid to challenge the status quo, even when that meant taking on the U.S. Army. In 2016, Palantir filed a lawsuit arguing that the Army had violated federal law by building its own battlefield intelligence system rather than evaluating commercial alternatives like Palantir's. The company ultimately won the case, setting a key precedent that government agencies must give serious consideration to existing commercial technologies before developing their own. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That rebellious spirit, says Piper Sandler analyst Brett Bracelin, exemplifies Palantir's 'unconventional journey.' 'The 22-year path to a ~$4 billion revenue run-rate with 40%+ FCF margins has been a long road travelled,' the analyst went on to say. 'While the culture, leadership, and journey may be unconventional, the impact in the AI revolution could be lasting.' Bracelin speaks from experience, having followed Palantir for more than five years – from its days as a buzzy late-stage private firm, through its direct listing in 2020, and into the stock's sharp decline in late 2022, when confidence in its long-term 30%+ growth ambitions faded and shares dropped to around $6. Yet, it's precisely this unpredictable trajectory that makes Palantir's comeback so compelling. Since that slump, the company has pulled off what Bracelin calls a ''rise of the phoenix' moment,' reemerging as an 'AI All-Star' on the strength of accelerating growth. While the stock isn't cheap – and still carries high risk – Bracelin argues it offers a 'one-of-a-kind growth+margin model' that could support a path to $24 billion in annual revenue by 2032, assuming it continues to expand in both the defense industry and the enterprise software sector – markets each worth over $1 trillion. In the government space alone, Bracelin sees potential for more than $10 billion in annual revenue by 2030, driven by a projected 36% compound annual growth rate (CAGR). That optimism is rooted in Palantir's proven 35% CAGR since 2018, a steady stream of new contracts with agencies like the Army, DoD, and Fannie Mae, and broader secular shifts in defense spending toward AI-powered software. The analyst also notes the strengthening ties between Palantir and traditional defense primes, which are evolving into strategic allies rather than competitors. But Palantir's growth story isn't confined to government contracts. Bracelin also highlights the U.S. commercial segment as a major opportunity, with revenues potentially growing at a 33% CAGR to surpass $5 billion by 2030. Key to this trajectory are partnerships with enterprise heavyweights like Accenture, Databricks, and SAP – and a growing footprint across industries ranging from finance to healthcare. Still, even the strongest bull case must reckon with valuation. Palantir's enterprise value to free cash flow (EV/FCF) multiple is sky-high – above 200x based on 2026 estimates. 'That said,' Bracelin noted, 'PLTR growth and margin metrics are in a class of one and if adoption continues to broaden, the bull-case of 30%+ compound growth and 40%+ FCF margin becomes more achievable, in our view.' In short, Bracelin sees Palantir as an 'AI secular winner' and has initiated coverage with an Overweight (i.e., Buy) rating. But while his Street-high $170 price target leads the pack, it implies only a modest 7% upside from current levels – a far cry from the triple-digit surge the stock has delivered over the past two years. (To watch Bracelin's track record, click here) And while Bracelin is firmly in the bull camp, the broader Street remains cautious. Palantir currently holds a Hold (i.e., Neutral) consensus rating, based on 10 Holds, 4 Buys, and 3 Sells. The average price target of $109.50 suggests shares could retreat 31% over the next 12 months. (See PLTR stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
USA Today
4 days ago
- USA Today
ICE, Army to build nation's biggest immigrant jail
A private company will build a 5,000-bed tent city to detain immigrants on Fort Bliss in Texas. The U.S. Army has hired a contractor to build the nation's largest ICE detention center, the latest move by President Donald Trump to use the military to deliver his promised mass deportations. Virginia-based Acquisition Logistics LLC will erect a temporary immigration detention center on Fort Bliss, in El Paso, Texas, near the southern border, with 5,000 beds, under a $232 million contract, according to the Department of Defense. It's likely the cost will rise. A similar tent city built to house unaccompanied migrant children on Fort Bliss in 2021 during the Biden administration ballooned within months to nearly $1 billion. Acquisition Logistics has served as a private contractor to the U.S. Navy, Air Force and Marines for more than a decade, according to federal procurement data. The company's website was "down for maintenance" on July 23, and USA TODAY couldn't reach a company representative online or by phone. Trump has vowed to deport millions of immigrants in the country illegally, and Congress recently appropriated $170 billion in new money to help him do it. The nation's system of immigration detention centers is under strain, as arrests of undocumented immigrants have risen in recent months. The White House touted its arrest record in a statement July 22: "Across the country, arrests of criminal illegal immigrants have soared as President Donald J. Trump makes good on his promise to rid our communities of these threats to public safety." The latest ICE data showed there were nearly 57,000 people in immigration detention, up from fewer than 40,000 at the close of the Biden administration.
Business Wire
4 days ago
- Business Wire
Law Offices of Howard G. Smith Encourages RxSight, Inc. (RXST) Investors To Inquire About Securities Fraud Class Action
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased RxSight, Inc. ('RxSight' or the 'Company') (NASDAQ: RXST) securities between , inclusive (the 'Class Period'). RxSight investors have until September 22, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN RXSIGHT, INC. (RXST), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On July 8, 2025, after the market closed, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in LDD sales, LAL utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. The Company's Chief Executive Officer, Ronald Kurtz, disclosed that '[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.' On this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025, on unusually heavy trading volume. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company was experiencing 'adoption challenges' and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight's products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Contact Us To Participate or Learn More: If you purchased RxSight securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
